Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Avallone

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Tumori|August 9, 2003
[Early evaluation using PET-FDG of the efficiency of neoadjuvant radiochemotherapy treatment in locally advanced neoplasia of the lower rectum]P Delrio, S Lastoria, A Avallone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2024
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF<sup>V600E</sup> wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trialD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open|January 5, 2023
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II studyC Cardone, A De Stefano, G Rosati, et al.
ESMO Open|January 5, 2021
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohortU Peretti, A Cavaliere, M Niger, et al.
ESMO Open|April 29, 2023
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancerG Martini, V Belli, S Napolitano, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancerV De Falco, P P Vitiello, D Ciardiello, et al.
ESMO Open|August 22, 2022
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)D Ciardiello, C Chiarazzo, V Famiglietti, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM studyD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2025
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trialD Ciardiello, G Martini, L Boscolo Bielo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2024
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE studyF Lordick, M E Mauer, G Stocker, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Tumori|August 9, 2003
[Early evaluation using PET-FDG of the efficiency of neoadjuvant radiochemotherapy treatment in locally advanced neoplasia of the lower rectum]P Delrio, S Lastoria, A Avallone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2024
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF<sup>V600E</sup> wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trialD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open|January 5, 2023
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II studyC Cardone, A De Stefano, G Rosati, et al.
ESMO Open|January 5, 2021
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohortU Peretti, A Cavaliere, M Niger, et al.
ESMO Open|April 29, 2023
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancerG Martini, V Belli, S Napolitano, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancerV De Falco, P P Vitiello, D Ciardiello, et al.
ESMO Open|August 22, 2022
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)D Ciardiello, C Chiarazzo, V Famiglietti, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM studyD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2025
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trialD Ciardiello, G Martini, L Boscolo Bielo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2024
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE studyF Lordick, M E Mauer, G Stocker, et al.
Pageof 7